Healthcare Asia’s business portfolio consists of a wide array of products in different oncology areas, stemming from its strong partnerships with suppliers in Europe and United States. Healthcare Asia monitors the list of new FDA-approved drugs closely to keep up with the ever-changing environment of the pharmaceutical industry.

The extensive range includes drugs such as but not limited to:

  • Iclusig (Ponatinib)
  • Keytruda (Pembrolizumab)
  • Lartruvo (Olaratumab)
  • Lysodren (Mitotane)
  • Opdivo (Nivolumab)
  • Tagrisso (Osimertinib)
  • Xtandi (Enzalutamide)
  • Yervoy (Ipilimumab)
  • Zelboraf (Vemurafenib)
  • Zejula (Niraparib)